Literature DB >> 12497658

Concurrent chemoradiotherapy in cervical cancer (a new paradigm in cervical cancer treatment).

Hee-Sug Ryu1.   

Abstract

During the last century, the mainstay for the treatment of uterine cervix cancer has been via two main primary treatment modalities, these being radical surgery (radical hysterectomy and regional lymph nodes dissection) and radiotherapy. Generally, radical surgery is restricted to stages I and IIa of FIGO (the International Federation of Gynecology and Obstetrics) Classification, while radiotherapy may be applied to all stages of cervical cancer. In 1999 the National Cancer Institute Clinical Announcement established concurrent chemoradiotherapy as a new primary treatment modality, which is the focus of this review.

Entities:  

Mesh:

Year:  2002        PMID: 12497658     DOI: 10.3349/ymj.2002.43.6.749

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  2 in total

1.  Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.

Authors:  Wenze Sun; Tao Wang; Fan Shi; Jiquan Wang; Juan Wang; Beina Hui; Yingbing Zhang; Jinli Lu; Hongwei Chen; Zi Liu
Journal:  BMC Cancer       Date:  2015-05-04       Impact factor: 4.430

2.  Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer.

Authors:  Tae Yeon Lee; Yi Jo Jeung; Chun Jun Lee; Heung Yeol Kim; Sung Han Kim; Won Gyu Kim
Journal:  Obstet Gynecol Sci       Date:  2013-01-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.